cliffwatch

tenofovir alafenamide fumarate · Gilead Sciences Inc · NDA 208464

Vemlidy

Earliest generic entry, as listed
15 Feb 2033

Blocked by patent: US 8754065, US 9296769.

Listed patents · 8 unexpired

PatentClaimsExpires
US 8754065—15 Feb 2033
US 9296769—15 Feb 2033
US 8754065substance, product, use U-388015 Aug 2032
US 8754065substance, product, use U-99915 Aug 2032
US 8754065substance, product, use U-127515 Aug 2032
US 9296769substance, product, use U-99915 Aug 2032
US 9296769substance, product, use U-388015 Aug 2032
US 9296769substance, product, use U-127515 Aug 2032

Exclusivities · 1 unexpired

NPPnew patient population27 Mar 2027

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • 25 Oct 2026Generic tentatively approved · 208464-001

Products covered · 1

NDA · productFormStrengthListed expiry
208464 · 001 · RLDtablet, oralEQ 25MG BASE15 Feb 2033